ホーム>>Signaling Pathways>> Others>>ADDA 5 hydrochloride

ADDA 5 hydrochloride

カタログ番号GC32251

ADDA 5 塩酸塩は、シトクロム c オキシダーゼ (CcO) の部分的な非競合的阻害剤であり、ヒト神経膠腫およびウシ心臓からの精製 CcO の IC50 はそれぞれ 18.93 μM および 31.82 μM です。

Products are for research use only. Not for human use. We do not sell to patients.

ADDA 5 hydrochloride 化学構造

Cas No.: 473268-46-1

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$92.00
在庫あり
5mg
$83.00
在庫あり
10mg
$142.00
在庫あり
25mg
$313.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

ADDA 5 hydrochloride is a partial non-competitive inhibitor of cytochrome c oxidase (CcO), with IC50s of 18.93 μM and 31.82 μM for purified CcO from human glioma and bovine heart, respectively.

ADDA 5 hydrochloride is a partial non-competitive inhibitor of CcO, with IC50s of 18.93 μM and 31.82 μM for purified CcO from human glioma and bovine heart, respectively. ADDA 5 inhibits CcO activity in UTMZ and Jx22-derived GSCs, with IC50s of 21.4 ± 3.9 μM and 15.5 ± 2.8 μM. ADDA 5 (25 μM) shows a growth inhibitory effect on UTMZ cells, with an EC50 of 8.17 μM[1].

ADDA 5 (8 mg/kg, i.p.) significantly suppresses the growth of tumor in mice. ADDA 5 does not causes detectable toxicity at up to 80 mg/kg in mice[1].

[1]. Oliva CR, et al. Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells. J Biol Chem. 2016 Nov 11;291(46):24188-24199. Epub 2016 Sep 27.

レビュー

Review for ADDA 5 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ADDA 5 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.